Shareholder Alert: Robbins LLP Announces Elanco Animal Health Incorporated (ELAN) Accused of Misleading Shareholders

Shareholder rights law firm Robbins LLP announces that a purchaser of Elanco Animal Health Incorporated (NYSE: ELAN) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between January 10, 2020 and May 6, 2020.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, June 30, 2020
Information
Tags: 
Legal, Professional services, Eli Lilly and Company, Coronavirus, Life sciences, Articles, Economy of the United States
Geotags: 
United States, California
⚠generated by AI ↴
Summary
Key Points: 
  • Shareholder rights law firm Robbins LLP announces that a purchaser of Elanco Animal Health Incorporated (NYSE: ELAN) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between January 10, 2020 and May 6, 2020.
  • Elanco is an animal health company that develops, manufactures, and markets products for companion and food animals.
  • According to the complaint, on March 24, 2020, Elanco withdrew its previously announced 2020 revenue and earnings per share guidance in light of the coronavirus pandemic.
  • However, Elanco assured investors "the Company is closely monitoring distribution logistics" and that "at this time, Elanco is not experiencing any supply disruption."


Shareholder rights law firm Robbins LLP announces that a purchaser of Elanco Animal Health Incorporated (NYSE: ELAN) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between January 10, 2020 and May 6, 2020. Elanco is an animal health company that develops, manufactures, and markets products for companion and food animals.

If you suffered a loss as a result of Elanco's misconduct, click here.

Elanco Animal Health Incorporated (ELAN) Accused of Misleading Shareholders

According to the complaint, on March 24, 2020, Elanco withdrew its previously announced 2020 revenue and earnings per share guidance in light of the coronavirus pandemic. However, Elanco assured investors "the Company is closely monitoring distribution logistics" and that "at this time, Elanco is not experiencing any supply disruption." Despite these assurances, on May 7, 2020, Elanco announced its first quarter 2020 results revealing revenue of $657.7 million and earnings per share of negative $0.12, reflecting “a reduction of approximately $60 million in channel inventory.” Elanco attributed the disappointing financial results to "distributor performance," among other things and assured investors the Company would "tighten [its] approach across many facets of [its] distributor relationships." On this news, Elanco's share price fell over 13% to close at $19.88 per share.

Elanco Animal Health Incorporated (ELAN) Shareholders Have Options

Contact us to learn more:

Leo Kandinov

(800) 350-6003

[email protected]

Shareholder Information Form

Want to be notified if a class action on behalf of Elanco settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Copyright: 
Copyright Business Wire 2020